Credit: Mohammed Haneefa Nizamudeen/Getty Images The next-generation, oral KRAS G12C inhibitor divarasib significantly reduces the risk for disease progression or death compared with existing KRAS-targeted treatments in patients with previously treated KRAS G12C-mutated advanced or metastatic non-small-cell lung cancer (NSCLC),...
Divarasib’s ORR was 58% vs 32% for sotorasib or adagrasib in the phase 3 Krascendo 1 trial. Dr Skoulidis discusses response, durability, and survival In this video interview, Ferdinandos Skoulidis, MD, PhD, highlights the importance of these efficacy findings, particularly...
Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer Skoulidis,a professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, described divarasib as a best-in-class inactive-state-selective KRAS G12C inhibitor....
Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer Key takeaways Sotorasib is an oral, irreversible KRAS G12C inhibitor. It was the first KRAS-targeted therapy approved by the FDA. It...
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer...
Biagio Ricciuti, MD, PhD, discusses KRASCENDO 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC Blocking RAS can be extremely synergistic with immunotherapies. When we block KRAS mutations with RAS inhibitors, and this has been...
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC The phase 3 Krascendo 1 trial (NCT06497556) showed that divarasib improved progression-free survival (PFS) and overall survival (OS) compared with sotorasib (Lumakras)...
Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers Key takeaways Adagrasib is an oral, irreversible KRAS G12C inhibitor. It covalently binds mutant KRAS G12C and stabilizes the inactive GDP-bound state. It is FDA...
Divarasib, a next-generation, oral KRAS G12C inhibitor, is more potent and selective in vitro than the first-generation KRAS G12C inhibitors sotorasib and adagrasib. In this phase 3, international, Original Article Share on Divarasib as Compared with Sotorasib or Adagrasib in...
October 30, 2026 3 min read Save Share LinkedIn Facebook X (Twitter) Bluesky Threads Email Copy Link Key takeaways: Patients assigned divarasib achieved longer OS and PFS than those assigned sotorasib or adagrasib, two standard-of-care agents. Fewer grade 3/grade 4...
